Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial

Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk. This investigation evaluated the effects of melatonin administration on metabolic status in diabetic patients with CHD.

Source: Clinical Nutrition - December 12, 2017 Category: Nutrition Authors: Fariba Raygan, Vahidreza Ostadmohammadi, Fereshteh Bahmani, Russel J. Reiter, Zatollah Asemi Source Type: research